CFMS - Conformis, Inc.
1.21 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 1.18 |
| Open | 1.19 |
| Bid | 1.11 x 3100 |
| Ask | 1.45 x 800 |
| Day's Range | 1.15 - 1.22 |
| 52 Week Range | 0.88 - 4.17 |
| Volume | 150,491 |
| Avg. Volume | 317,985 |
| Market Cap | 76.439M |
| Beta | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.01 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.33 |
- GlobeNewswire•7 days ago
Conformis Announces Settlement of Patent Dispute with Smith & Nephew
BILLERICA, Mass., Sept. 17, 2018-- Conformis, Inc., a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants ...
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of CFMS earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 ConforMIS Inc Earnings Call
- Simply Wall St.•17 days ago
Do You Know Conformis Inc’s (NASDAQ:CFMS) Cash Situation?
Two important questions to ask before you buy Conformis Inc (NASDAQ:CFMS) is, how it makes money and how it spends its cash. This difference directly flows down to how muchRead More...
- GlobeNewswire•19 days ago
Report: Developing Opportunities within Powell Industries, ConforMIS, Heska, Gevo, QAD, and Northeast — Future Expectations, Projections Moving into 2018
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD ...
- GlobeNewswire•2 months ago
Conformis announces election of Carrie Bienkowski to its Board of Directors
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today that its Board of Directors elected Carrie Bienkowski to the Board effective July 31, 2018. Ms. Bienkowski will serve as a class I director until the Conformis 2019 Annual Meeting of Stockholders. “We welcome the addition of Carrie Bienkowski to our Board of Directors,” said Kenneth P. Fallon, III, Chairman of the Board of Directors of Conformis. “Her knowledge in consumer marketing and digital innovation will be a great asset for Conformis.” “Carrie’s experience is consistent with the opportunity we have to position the Conformis brand among today’s active and engaged patients that are seeking orthopedic treatment," added Mark Augusti, Conformis’ President and Chief Executive Officer.
- Associated Press•2 months ago
ConforMIS: 2Q Earnings Snapshot
The Billerica, Massachusetts-based company said it had a loss of 24 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Conformis Announces the first 3D Total Hip Replacement Surgeries performed at JFK Medical Center in Florida
Conformis, Inc. (CFMS), a medical technology company that offers patient conforming joint replacement implants, today announced completion of the first two Conformis Hip System implants. The Conformis Hip System is the first ever 3D designed primary total hip replacement system. The first surgeries were performed by Gregory Martin, M.D., Joint Fellowship Trained Orthopedic Surgeon and founder of Personalized Orthopedics of the Palm Beaches, and took place at a leading HCA Facility, JFK Medical Center in Atlantis, Florida on July 31, 2018.
- GlobeNewswire•2 months ago
Conformis Reports Second Quarter 2018 Financial Results
BILLERICA, Mass., Aug. 01, 2018-- Conformis, Inc., a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint ...
- Zacks•2 months ago
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
- InvestorPlace•2 months ago
5 Top-Ranked Stocks to Benefit From Rising P/E Investing
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA
- Zacks•2 months ago
5 Top-Ranked Stocks to Benefit From Rising P/E Investing
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- ACCESSWIRE•2 months ago
Free Technical Research on IsoRay and Three More Medical Supplies Equities
On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).
- GlobeNewswire•2 months ago
Conformis to Host Second Quarter 2018 Financial Results Webcast on August 1, 2018
BILLERICA, Mass., July 12, 2018-- Conformis, Inc. announced today that it will host a webcast on Wednesday, August 1, 2018, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ...
- Simply Wall St.•3 months ago
When Will Conformis Inc (NASDAQ:CFMS) Become Profitable?
Conformis Inc’s (NASDAQ:CFMS): ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The US$76.75m market-cap company’s loss lessens since it announced a -US$53.58m bottom-line in theRead More...
- ACCESSWIRE•3 months ago
Initiating Free Research Reports on DENTSPLY SIRONA and Three Other Medical Supplies Equities
For today, WallStEquities.com assesses the recent performance of Conformis Inc. (NASDAQ: CFMS), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Illumina Inc. (NASDAQ: ILMN), and Integra LifeSciences Holdings Corp. (NASDAQ: IART). Companies in the Medical Instruments and Supplies manufacturing industry primarily research, develop, and produce non-electronic medical, surgical, dental, and veterinary instruments and apparatus.
- ACCESSWIRE•4 months ago
Agilent Technologies and Three More Healthcare Stocks Under Our Scanner
This Thursday, WallStEquities.com has initiated reports coverage on the following Healthcare equities: ConforMIS Inc. (NASDAQ: CFMS), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Agilent Technologies Inc. (NYSE: A), and Biocept Inc. (NASDAQ: BIOC). Billerica, Massachusetts headquartered ConforMIS Inc.'s stock finished Wednesday's session 2.19% lower at $1.34 with a total trading volume of 380,145 shares.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CFMS earnings conference call or presentation 2-May-18 8:30pm GMT
Q1 2018 ConforMIS Inc Earnings Call
- Associated Press•5 months ago
ConforMIS: 1Q Earnings Snapshot
The Billerica, Massachusetts-based company said it had a loss of 22 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
- Simply Wall St.•5 months ago
Are ConforMIS Inc’s (NASDAQ:CFMS) Interest Costs Too High?
Investors are always looking for growth in small-cap stocks like ConforMIS Inc (NASDAQ:CFMS), with a market cap of US$78.79M. However, an important fact which most ignore is: how financially healthyRead More...
